Citizens Maintains Market Outperform on KalVista Pharmaceuticals, Lowers Price Target to $28

Benzinga Newsdesk www.benzinga.com Negative 95.0%

Neg 95% Neu 0% Pos 0%

Citizens analyst Jonathan Wolleben maintains KalVista Pharmaceuticals (NASDAQ:KALV) with a Market Outperform and lowers the price target from $29 to $28.